Introduction. Immune mechanisms are currently recognized as an integral part of the multifactorial etiology of hypertension and related organ damage.

Aim. To study autoimmune antibodies in pregnant women with chronic arterial hypertension for the prediction and prevention placenta-associated pregnancy complications, which in turn will reduce the incidence of adverse perinatal pregnancy outcomes.

Materials and methods. The study included 115 patients, 85 patients (the main group) with hypertension, 30 patients (the control group) with the physiological course of pregnancy, without hypertension. All patients in the study groups underwent the determination of autoimmune antibodies using ELIPP complex methods.

Results. A statistical deviation of the spectrum of autoimmune antibodies was observed in women with arterial hypertension, namely, a deviation of the spectrum to β2 – glycoprotein, autoantibodies to collagen, autoantibodies to protein S100, autoantibodies to cytoplasmic antigen of vascular endothelial cells (ANCA), autoantibodies to platelet membrane protein (TrM), autoantibodies to membrane antigen of glomerular kidney cells (KiMS).

Conclusions. The results of the study demonstrate the role of autoantibodies in the development of placenta-associated pregnancy complications in patients with chronic arterial hypertension. The determination of autoimmune antibodies will reduce the frequency of adverse perinatal outcomes.

Uterine fibroids are benign tumors of the myometrium that affect more than 70% of women worldwide. Due to the high prevalence, the economic costs of the health system and the significant impact on women’s quality of life, uterine fibroids pose a serious problem both for each individual woman with this diagnosis and for the health care system as a whole. Genetic factors play a significant role in the formation of uterine fibroids. The article examines current data on the genetic determinants of uterine fibroids, obtained as a result of the analysis of full-genomic studies (GWAS) and subsequent replicative studies. At this point in time, materials from 8 GWAS and 5 replicative studies of uterine fibroids are presented in the literature. According to GWAS data, more than 50 different candidate genes involved in the development of the disease have been identified. However, only 19 genes (CDC42/WNT4, GREB1, ACTRT3/TERC/MYNN/LRRC34, SCFD2/LNX1, SULT1B1, TERT, FGFR4, SYNE1/ESR1, KANK1/ DMRT1, SLK/OBFC1, WT1/CD44/PDHX, BET1L/RIC8A/SIRT3/PSMD13, ATM/C11orf65, SLC38A2, LINC0/FOXO1/FLJ42392, SHBG/TP53, MCM8/TRMT6, TNRC6B, MED12/TEX11/SLC7A3) have shown an association with uterine fibroids in two or more GWAS studies. In 5 conducted replicative studies of uterine fibroids, the involvement in the formation of the disease was confirmed for only 2 (BET1L and TNRC6B) of more than 50 significant candidate genes for uterine fibroids known to date by GWAS. This dictates the need to continue further genetic and epidemiological studies of uterine fibroids in different ethno-territorial groups.

This review is aimed to analyse research data on the lower genital tract microbiome and factors effecting its composition, as well as the relationship with HPV-associated cervical diseases. Modern studies show that certain types of lactobacilli can play a protective role by reducing the likelihood of human papillomavirus (HPV) infection and contributing to its elimination. At the same time, dysbiotic changes, including decreased levels of lactobacilli and increased levels of opportunistic pathogens, are associated with the development of bacterial vaginosis and other abnormal vaginal biocenosis. These conditions can contribute to the persistence of HPV, increasing the risk of cervical intraepithelial neoplasia and cervical cancer. Most studies show significant differences in the vaginal microbiome composition in women with cervical intraepithelial neoplasia and malignant cervix neoplasms as compared to healthy patients. Anaerobic bacteria such as Gardnerella vaginalis, Mobiluncus spp., Peptoniphilus spp., Parvimonas micra, Prevotella spp. that can inhibit the growth of lactobacilli and disrupt the normal balance of microflora play an important role in this process. In addition, decreased levels of Lactobacillus crispatus are associated with a higher probability of HPV persistence and dysplasia progression. Studying mechanisms of interaction between vaginal microbiota and HPV is critically important to understand the mechanisms of pathogenesis of precancerous and malignant processes of the cervix. Further study of these aspects will allow the development of new prevention and treatment strategies to modulate vaginal microflora and reduce the risk of disease progression.

Introduction. Teenage pregnancy is recognized by WHO as a serious public health problem, it is widespread throughout the world: both in developed and developing countries.

Aim. To demonstrate the resources of the regional service of pediatric and adolescent gynecology to reduce unwanted reproductive outcomes in minors.

Materials and methods. The study was conducted in obstetric hospitals of the Tyumen region, medical institutions providing outpatient gynecological care to minors. Contingent: 1703 minors with pregnancies completed in 2016–2023. Depending on the pregnancy outcome, the study contingent was divided into two groups. Group 1: 1,173 teenage girls with pregnancies that ended in childbirth. Group 2: 531 teenage girls with an abortive outcome of pregnancy. A separate review of clinical cases of ectopic pregnancy in minors is given (3 cases).

Results. During the period under review, 156,747 pregnancies ended in childbirth in the Tyumen Region (excluding the KhantyMansi Autonomous Okrug – Yugra and the Yamalo-Nenets Autonomous Okrug). Over 6 years, there was a decrease from 23,791 to 17,164 births, i.e. by 27.9%. Statistics on childbirth and abortive outcomes in minors demonstrate a significant reduction in the number of completed pregnancies in minors: from 282 in 2016 to 175 in 2023 (-37.9%). The frequency of pregnancies with an abortive outcome in minors is higher than in adult women. Medical abortion accounts for almost ¾ of pregnancy terminations in minors. There is no significant decrease in the frequency of pregnancy terminations in adolescent girls among minors.

Conclusion. A stable improvement in the situation in this area is possible provided that state programs (federal, regional) are developed and implemented, targeted funding for activities aimed at preserving the reproductive health of children and adolescents, and grant support for scientific research.

Introduction. Due to the plasma volume expansion prevailing over the increase in red blood cell production, as well as inadequate dietary intake with underlying physiologically increased iron requirements, pregnant women tend to suffer from iron deficiency and anaemia.

Aim. To evaluate the efficacy of Tardyferon (depot iron (II) sulphate 80 mg) in pregnant women with anaemia in reducing adverse perinatal outcomes. 

Materials and methods. To conduct the retrospective chart review of pregnant women of Stavropol Krai, the patients were divided into 2 groups: Group 1 (n = 70) – the treatment group, which included pregnant women who were diagnosed with IDA in the 1st, 2nd or 3rd trimesters and who received antianemic therapy, and Group 2 (n = 30) – pregnant women with IDA (diagnosed in the 3rd trimester) who did not use any iron supplements.

Results. In Group I, haemoglobin levels identified at the time of detection of anaemia ranged from 91 to 109 g/l (103.1 ± 4.5), red blood cell counts from 2.7 to 4.1 × 109/l (3.5 ± 0.3), and hematocrit levels from 26 to 37 (32.9 ± 1.8). Once the diagnosis of anaemia had been established, pregnant women were prescribed with Tardiferon 80 mg twice a day, which they administered on a regular basis until delivery and continued using during the postpartum period. In Group 2, patients did not receive any iron supplements and showed a gradual decrease in haemoglobin levels by an average of 5.6 g/l. Pregnant women receiving Tardyferon prolonged-release tablets from the date when anaemia was diagnosed showed an increase in clinical blood test values.

Conclusions. In pregnant women with anaemia, iron therapy normalizes haematological parameters, which leads to improved tissue oxygen supply and a favourable clinical effect.

Chronic non-infectious dermatoses of the anogenital area comprise a heterogeneous group of diseases characterized by varied etiopathogenesis, clinical manifestations, disease course, and prognosis. Treatment of dermatological conditions in the anogenital area often presents a complex challenge and necessitates an interdisciplinary approach. Traditionally, comprehensive therapy is employed, including agents aimed at restoring the cutaneous barrier, topical anti-inflammatory medications, particularly glucocorticosteroids and/or topical calcineurin inhibitors, and less frequently, systemic glucocorticosteroids, retinoids, hydroxychloroquine, or dapsone, as well as interventions targeting the alleviation of subjective symptoms and the prevention and treatment of secondary infections. The purpose of this publication is to discuss the fundamental aspects of baseline therapy for chronic non-infectious dermatoses of anogenital area. Baseline therapy is defined as a set of interventions that a patient with a dermatosis receives over a prolonged or continuous period, even during disease remission. Approaches to baseline therapy for dermatoses of anogenital area are poorly developed and require further clarification. Nevertheless, the regulation of the spectrum and quantity of agents used by the patient on the genital and perianal areas, the elimination of irritants, normalization of daily hygiene practices, and the use of agents that restore the cutaneous barrier are crucial components of comprehensive therapy for skin diseases in this anatomical location. One of the key aspects of successful treatment of dermatoses of anogenital area is the restoration of the cutaneous barrier, which can be disrupted by both the underlying disease processes and exposure to external factors. This article details the effects of preparations based on 5% dexpanthenol, which is regarded as a moisturizing and wound-healing agent. Dexpanthenol demonstrates significant anti-inflammatory activity, comparable to that of corticosteroids. Its use in therapy not only improves skin condition but also enhances the efficacy of cjrticosteroids, which is particularly important for patients requiring long-term management of dermatoses.

Introduction. One of the actual problems of urgent gynecology is diseases included in the symptom complex “acute abdomen”, because today there are no algorithms for examining this cohort of patients of reproductive age, and existing clinical guidelines explain only part of the diagnostic standards of individual groups.

Aim. To improve diagnostic criteria and optimize tactics for managing patients with the symptom complex acute abdomen in order to preserve reproductive function.

Materials and methods. A retrospective analysis of 785 emergency laparoscopic surgeries performed from 2017 to 2020 was carried out at one of the clinical sites of the Department of Obstetrics and Gynecology, Faculty of Medicine, RNIMU named after N.I. Pirogov. A comparison of preand postoperative diagnoses, an analysis of diagnostic algorithms, and treatment outcomes of patients with suspected acute abdomen were carried out. The role of laparoscopy as a highly informative method of differential diagnosis in the presence of the symptom complex acute abdomen is shown.

Results. Based on the conducted retrospective analysis, an algorithm for managing female patients of reproductive age with the symptom complex acute abdomen was developed: at the first stage, it includes a diagnostic search with a decision on the need for emergency surgical treatment, mandatory joint examination by a surgeon and an obstetrician-gynecologist. At the second stage, in case of choosing a conservative management tactic, patients need to undergo extended clinical and laboratory diagnostics, determine the effectiveness of the therapy, and, if necessary, set indications for delayed surgical treatment.

Conclusions. Thus, only improving the quality of differential diagnostics, including instrumental research methods, will help avoid unnecessary surgical aggression, which will ultimately lead to the preservation and implementation of reproductive function in female patients of reproductive age.

The article presents an analysis of the literature data on the modern possibilities of hormonal intrauterine contraceptive systems. Intrauterine systems (IUDs) are one of the most effective, safe and acceptable methods of contraception. According to statistics, about 1/3 of the female population of Russia, 1/2 – women of East Asia use IUD as contraception, which is most likely due to the lack of opportunity and desire for constant monitoring of the use of contraceptives (pills, patch, intravaginal ring). In a number of studies conducted in the last 10 years, there has been a more than threefold increase in the frequency of IUD use in women aged 15–24 years. Until recently, hormonal IUDs (Mirena) were usually used in women who gave birth, but the development of a new IUD, Kailin, containing 19.5 mg of levonorgestrel, is actively used in more than 30 countries around the world as a highly effective and acceptable method of contraception with a low content of LNG. Many studies have been conducted to investigate the effectiveness, acceptability and safety of IUD. Thus, in one of the largest prospective observational multicenter KYSS study, satisfaction with the use of IUD LNG was assessed for one year. The study included 1,114 women. The results of the study showed: satisfaction with this method of contraception in 86.1% of women, the desire to continue using Kailina – 81.4%, as well as a low percentage (16.9%) of adverse events. Therefore, IUD-LNG IUD is an effective, acceptable, safe method of contraception that allows to prevent the onset of unwanted pregnancy, including in young unborn women. 

Introduction. Currently, there is a high frequency of vaginal microbiocenosis disorders (85–90%) in the postoperative period in patients with various nosological forms of gynecological diseases requiring surgical treatment.

Aim. To study the efficacy and tolerability of Depantol®, a combination of an antiseptic and a reparant complex, for the prevention and treatment of postoperative infectious and inflammatory complications of the lower genital tract after surgical interventions performed through vaginal access.

Materials and methods. A prospective comparative study involving 588 patients who underwent vaginal surgery was designed to evaluate the efficacy of Depantol® in the prevention and treatment of infectious and inflammatory complications of the lower genital tract. The first group consisted of 98 patients who underwent vaginal hysterectomy, vaginal wall plastic surgery and/or transsacrospinal hysteropexy and standard postoperative management; the second group consisted of 236 patients who underwent vaginal hysterectomy and vaginal wall plastic surgery; in addition to standard therapy for 10 days, the patients received Depantol® 1 suppository 2 times a day for 10 days; the third – 254 patients after transsacrospinal hysteropexy, who received Depantol in the postoperative period, according to the instructions for use.

Results. The results of the study demonstrated that clinical symptoms 14 days after treatment were observed in 49.9% of patients in the first group, 2.1% in the second, and 1.5% in the third, which may indicate a favorable effect of Depantol on the processes of trophism and regeneration of vaginal tissues, which is confirmed by 25% (OR 0.3 (CI: 0.11–0.71, p < 0.05), RR 0.25 (CI: 0.14–0.46, p < 0.05)) less pronounced hyperemia of the postoperative wound in patients of the second and third groups than in patients of the first group.

Conclusions. The long-term results of the study allow us to recommend Depantol, with high compliance, good tolerability, a favorable safety profile, corresponding to the principles of FTS-active management of the postoperative period in patients after vaginal surgeries, in order to accelerate recovery by optimizing rehabilitation, reducing microbial contamination of the vagina, and enhancing the epithelialization processes of the postoperative wound.

Stress-related menstrual cycle disorders (MCDs) is a common reason for seeking gynecological care. Due to their functional origin, MCDs need better adaptive reserve restoration rather than hormonal intervention, at least at the first stage of treatment. Resistance against the action of stressors and predisposition to develop stress-related disorders are determined by genetic and modifiable factors, not least of which is the nutritional status of individuals. The nutritional status can be corrected by a wide use of vitamins, minerals and plant extracts with antioxidant effects and properties regulating neuroendocrine response to stress. Such nutrient substances may be administered in accordance with the physiological needs of the follicular/ proliferative and luteal/secretory phases of the menstrual cycle. Biologically active food additives derived from foods contribute to the development of a systemic neurohormonal response and cell adaptation to stress. They have comprehensive and multidirectional effects, which are important for the proper functioning of the reproductive system. Alternative or supplemental products are increasingly used in the therapy of any and all diseases and pathological conditions. Short-term menstrual cycle disorders such as oligomenorrhea or high variability in cycle length due to stress factors can be resolved in the context of therapeutic lifestyle modification using biologically active food additives with antioxidants and adaptogenic effects without additional prescription of hormone therapy. Biologically active food additives can be used as supplemental non-medicinal products as part of complex therapy in other menstrual cycle disorders or endocrine diseases.

Prevention and management of iron deficiency conditions, including iron deficiency anemia (IDA), in women is an important global health problem. Iron deficiency affects not only the somatic, but also the reproductive health of women, and may lead to decreased fertility. Prevention and management of anemia in pregnant women is essential, as iron deficiency can adversely affect the maternal and fetal well-being. In Russia, anemia is found in 35.5% of pregnant women. The market offers a wide range of iron supplements. Biand trivalent oral iron supplementation is often the first-line prevention and management for iron deficiency conditions, as it is an easy, affordable and effective therapy option. These supplements are not always effective; intestinal disorders and inflammatory diseases may reduce iron absorption. In addition, adverse effects, first of all gastrointestinal (GI) ones, such as abdominal pain, dyspepsia, nausea, vomiting, diarrhea or constipation often limit the use of iron supplements. The causes of GI mucosal injury include the direct toxic effect of iron ions on enterocytes, increased production of intestinal reactive oxygen species, and disruption of the gut microbiota. Intravenous iron therapy can cause iron overload, hypophosphatemia, potential risks of kidney injury and stimulation of atherosclerosis. Liposomal iron is a promising strategy for iron deficiency anemia management. Liposomes ensure absorption of iron from the intestinal lumen by the microfold cells (M cells) of the small intestine, and then by the lymphatic system, thus avoiding hepcidin control over absorption. Liposomal iron is significantly less toxic and is well tolerated by patients. Liposome properties are dependent on the phospholipids that form the lipid bilayer; sunflower lecithin is one of the promising alternatives.

Introduction. Urethral pain syndrome (UPS) is a little-studied issue.

Aim. To determine the role of intracellular infections in the UPS etiology and evaluate the efficacy of azithromycin in the treatment of UPS.

Materials and methods. A total of 18 female patients with UPS were included in the study. In addition to standard diagnostic procedures, urethra palpation and PCR examination of urethral discharge were performed. Quality of life was assessed using the SF-36 questionnaire filled out by the patients. Along with pathogenetic drugs, all patients received antibacterial therapy in the form of azithromycin (Azithromycin Express) according to the following scheme: 1.0 g as a single dose on Day 1, followed by 500 mg once daily for three days (the cycle dose is 2.5 g). The efficacy of treatment was estimated as a decrease in pain intensity after 7 days. The quality of life, pathogen eradication and pain intensity were assessed 2 months after completion of therapy. In addition, 73 domestic and foreign publications devoted to the issue of diagnosis and treatment of UPS were reviewed.

Results. On the day of presentation, Chlamydia trachomatis was detected in 5 patients, and Mycoplasma genitalium was detected in 12 patients. The leukocyte counts in urine averaged 12.7 ± 2.3. All patients had bacteriuria with a titer of 102–103 CFU/ml. The total pain intensity score averaged 7,2 ± 0,8. The quality of life scores measured by the SF-36 scale was 15.2 ± 1.7. After a week, the pain intensity decreased on average to 3.2 ± 1.7. During a follow-up examination after 2 months, C. trachomatis was not detected in the urethral scraping, and M. genitalium DNA was only detected in 1 patient. The pain intensity in the urethra averaged 1.4 ± 0.1. Therefore, the quality of life increased significantly (21.7 ± 0.9 scores).

Conclusion. The antibiotic prescription in UTS is justified. UTS cannot be considered an uncomplicated chlamydia infection, so we prescribed more than a single dose. Further research is needed to develop an optimal treatment regimen, including antibacterial one, for patients with UTS.

Introduction. The consequences of these mixed nonspecific vaginitis are manifested in the aggravation of the course of the disease, the complexity of diagnosis and the choice of therapy.

Aim. Evaluation of the clinical and microbiological efficacy of a complex drug including clindamycin and butoconazole in local therapy of patients with mixed forms of nonspecific bacterial-fungal vaginal infections.

Material and methods. 126 patients with a confirmed diagnosis of “mixed nonspecific bacterial-fungal vulvovaginitis”. The proposed therapy is a vaginal cream containing clindamycin phosphate and butoconazole nitrate (1 dose (5.0 g) for 6 days). Clinical and microbiological efficacy was assessed at 14 days (22 ± 3 days from the start of therapy – stage V2), 1 month (40 ± 3 days from the start of therapy – stage V3) and 3 months (100 ± 3 days from the start of therapy – stage V4) after the end of therapy.

Results. Topical use of a drug containing an antibiotic (clindamycin phosphate) and an antimycotic (butoconazole nitrate) contributes to the leveling of clinical symptoms in the form of itching and dyspareunia, respectively, in 94.45% and 92.9%, pathological whites in 91.3% of women, normalization of the pH of vaginal secretions in 92.1% of patients. Microbiological efficacy at the end of the follow-up period was 88.1% (Hay/Ison Grade 1 and 2), 90.5% (Donders Grade <3) and 86.5% PCR.

Conclusion. Clinical and microbiological evaluation of the use of containing an antibiotic (clindamycin phosphate) and an antimycotic (butoconazole nitrate) as a seven-day therapy, having a wide range of antibacterial and antimycotic activity with good tolerability, has shown high efficacy in the treatment of patients diagnosed with mixed nonspecific bacterial-fungal vulvovaginitis, which allows it to be recommended for the treatment of women with This nosology, and also offers a safe and effective option for empirical therapy of various vaginal infections.

Introduction. Bronchopulmonary dysplasia (BPD) is a chronic lung disease in children, which is a complication of premature birth, associated with adverse neurological outcomes, high incidence of respiratory morbidity and mortality. Currently, a new recommended method for the prevention of BPD has appeared using inhalation administration of the surfactant drug Tauractant.

Aim. Аnalyze the dynamics of the scoring of the ultrasound picture of the lungs during the inhalation administration of Tauractant, prescribed for the prevention of BPD.

Materials and methods. The study was conducted at the State Budgetary Healthcare Institution of the Sverdlovsk Region “Yekaterinburg Clinical Perinatal Center” in the period from 27.01.2024 to 27.01.2025. Included 14 children with a gestational age of < 30 weeks, who received respiratory therapy by the methods of nasal CPAP or mechanical ventilation by the 8–14th day of life.

Results. During our study and analysis, we noted cases of decreasing the intensity of respiratory therapy, namely: one child was extubated and transferred to nasal CPAP; two children initially on CPAP were transferred to low-flow nasal cannulas (LFNC); one child initially on CPAP was transferred to free-flow O2. Comparative analysis of such parameters as the frequency of mechanical ventilation, PiP parameters, LFNC frequency, FiO2, as well as the score according to lung ultrasound before the 1st and after the 5th dose of Tauractant did not show statistically significant differences in the main study sample (p > 0,05).

Conclusion. Inhalation use of Tauractant for the prevention of BPD in premature infants is a new and promising method that probably reduces the risk and severity of respiratory injury. However, at present there are limited data on the use of this technique and additional studies are required to determine its effectiveness and safety.

Introduction. In the context of iron deficiency states in women of reproductive age and, as a result during pregnancy, leads to the formation of the gestational complications and negatively perinatal outcomes. The routine screening for the detection of iron deficiency by determining the level of ferritin allows you to formed risk groups in order to carry out timely correction.

Aim. To estimate the level and rate of an iron deficiency state in pregnant women in the first trimester.

Materials and methods. The study included 401 pregnant women under surveillance in the period from January to June 2023. The main group was 134 patients with a diagnosis of iron deficiency – 33.4% of the total number of examined. The comparison group is represented by 36 pregnant women with the level of serum ferritin 41 – 60 ug/l.

Results. The mean age and gestation of patients in the main and control groups were 27.9 (6.1) and 28.7 (6.8) years and 10.7 (1.9) and 10.6 (1.8) weeks, respectively. The serum ferritin level was 20.57 ± 8.83 ug/l in the patients of the main group and was significantly lower compared to the control group 49.74 ± 6.96 ug/l (p = 0.01). Among the patients in the main group, more than 80% had severe absolute iron deficiency (SF concentration < 15 ug/l), detected in 29.1% of women (39/134) and absolute iron deficiency (SF concentration ≥ 15 – < 30 ug/l) – 52.9% of cases (71/134). Features of the observation showed that in the 2nd trimester of pregnancy in patients with iron deficiency, the diagnosis of anemia was detected 2.6 times more often – 31.3% (42/134) compared to the control group.

Conclusions. Determination of serum ferritin allows to identify patients with iron deficiency and timely prescribe iron preparations in preventive/therapeutic doses to reduce the frequency of perinatal and maternal complications.

Introduction. The aim is to evaluate the efficacy and safety of the use of micronized estriol produced in the form of a vaginal cream in the preoperative period in patients with pelvic floor muscle failure in postmenopause.

Aim. To evaluate the efficacy and safety of the use of micronized estriol in the preoperative period in patients with pelvic organ prolapse (POP) in postmenopause.

Results. The effectiveness of therapy with the studied drug made it possible to obtain a rapid clinical effect with a significant improvement in the condition of the mucous membranes and a decrease in the manifestation of IVA in patients already at the end of the first week of use. No side effects or adverse events were detected against the background of Ovestin use.

Conclusion. The experience of preoperative preparation using Ovestin (Aspen Bad Oldesloe GmbH, Germany), in the form of a vaginal cream (1 mg/g, 15 g, with a calibrated applicator) in patients with genital prolapse in postmenopausal provides restoration of the structure and elasticity of the vaginal mucosa, which contributes to the uncomplicated course of the postoperative period.

Approximately one in five men or women develops some form of malignant neoplasm (MN) in their lifetimes. Around one in nine men and one in 12 women die from cancer. Ten major types of cancer comprise two-thirds of all new cases of cancer. Now, we can witness a change from impersonal treatment efficacy assessment to a personalized approach, including an analysis of cancer patient’s QoL, his/her age, comorbidity, stage, and immunohistochemical and molecular genetic characteristics of the tumour process. Despite revolutionary advancements in understanding of the molecular biology of tumours, innovative techniques in the development of cytoreductive and anti-tumour treatments, cancer remains one of the most serious health challenges and a leading cause of death worldwide. Challenges in early diagnosis of cancer, the absence of clear markers for tissue "readiness" for tumour growth, the inadequacy of the principle of anti-tumour therapy personalization and a number of other issues do not allow to get out of the vicious circle. The epidemiology of oncological conditions is characterized by gender differences. Breast, lung, and colorectal cancers are the most commonly reported cancer in women. Modern advances in oncology have led to an increase in survival rates in cancer female patients. However, anti-tumour therapy (AT) is characterized by a diverse array of toxic effects on organs and systems. In women, AT is often complicated by premature ovarian failure (POF). Therefore, a significant percentage of women need to u se menopausal hormone therapy (MHT) after successful completion of cancer treatment. This article presents the results of the search for information about the acceptability of MHT for female patients after treatment of non-gynecological cancers, as well as alternative therapy options for menopausal disorders.